secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001193125-23-091610
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus CEO Kenneth Reali departs; Anthony Bihl named interim CEO
-------------------------------------------------------------------

- CEO Kenneth Reali transitioned from role on April 3, 2023; resigned as director and officer on April 4.
- Anthony P. Bihl III appointed interim CEO and Class III director effective April 5, 2023.
- Bihl previously served as CEO of Bioventus LLC (2013-2020) and has public board experience.
- Separation agreement provides severance: 18 months base salary, 150% of target bonus, COBRA.
- Company states Reali's departure is not related to its operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523091610/0001193125-23-091610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523091610/d474824d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-091610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer